

STERIS plc  
**Consolidated Condensed Statements of Operations**  
(In thousands, except per share data)

|   | Three Months Ended<br>March 31, |                     | Twelve Months Ended<br>March 31, |                     |
|---|---------------------------------|---------------------|----------------------------------|---------------------|
|   | 2024<br>(Unaudited)             | 2023<br>(Unaudited) | 2024<br>(Unaudited)              | 2023<br>(Unaudited) |
| <b>Revenues</b>   | \$ 1,419,387                    | \$ 1,281,252        | \$ 5,138,701                     | \$ 4,536,266        |
| <b>Cost of revenues</b>   | 836,485                         | 734,850             | 2,920,541                        | 2,555,540           |
| <b>Gross profit</b>   | 582,902                         | 546,402             | 2,218,160                        | 1,980,726           |
| <b>Operating expenses:</b>  |                                 |                     |                                  |                     |
| Selling, general, and administrative  | 309,063                         | 286,853             | 1,252,318                        | 1,090,663           |
| Research and development  | 27,462                          | 25,514              | 103,679                          | 98,477              |
| Restructuring expenses  | 26,043                          | 358                 | 26,045                           | 485                 |
| <b>Total operating expenses</b>   | 362,568                         | 312,725             | 1,382,042                        | 1,189,625           |
| <b>Income from operations</b>   | 220,334                         | 233,677             | 836,118                          | 791,101             |
| <b>Non-operating expenses, net</b>  | 29,759                          | 30,275              | 133,308                          | 110,835             |
| <b>Income from continuing operations before income tax expense</b>            | 190,575                         | 203,402             | 702,810                          | 680,266             |
| <b>Income tax expense</b>   | 37,276                          | 21,203              | 149,530                          | 124,069             |
| <b>Income from continuing operations, net of income tax</b>                   | \$ 153,299                      | \$ 182,199          | \$ 553,280                       | \$ 556,197          |
| <b>(Loss) income from discontinued operations, net of income tax</b>          | \$ (154,301)                    | \$ 4,765            | \$ (173,201)                     | \$ (450,384)        |
| <b>Net (loss) income</b>  | \$ (1,002)                      | \$ 186,964          | \$ 380,079                       | \$ 105,813          |
| <b>Less: Net income (loss) attributable to noncontrolling interests</b>       | 375                             | (261)               | 1,840                            | (1,217)             |
| <b>Net (loss) income attributable to shareholders</b>                         | \$ (1,377)                      | \$ 187,225          | \$ 378,239                       | \$ 107,030          |
| <b>Earnings per ordinary share (EPS) - Basic</b>                              |                                 |                     |                                  |                     |
| Continuing Operations   | \$ 1.55                         | \$ 1.84             | \$ 5.58                          | \$ 5.59             |
| Discontinued Operations   | \$ (1.56)                       | \$ 0.05             | \$ (1.75)                        | \$ (4.52)           |
| Total   | \$ (0.01)                       | \$ 1.89             | \$ 3.83                          | \$ 1.07             |
| <b>Earnings per ordinary share (EPS) - Diluted</b>                            |                                 |                     |                                  |                     |
| Continuing Operations   | \$ 1.54                         | \$ 1.83             | \$ 5.55                          | \$ 5.56             |
| Discontinued Operations   | \$ (1.55)                       | \$ 0.05             | \$ (1.74)                        | \$ (4.49)           |
| Total   | \$ (0.01)                       | \$ 1.88             | \$ 3.81                          | \$ 1.07             |
| <b>Cash dividends declared per share ordinary outstanding</b>                 | \$ 0.52                         | \$ 0.47             | \$ 2.03                          | \$ 1.84             |
| <b>Weighted average number of shares outstanding used in EPS computation:</b> |                                 |                     |                                  |                     |
| Basic number of shares outstanding  | 98,851                          | 99,055              | 98,787                           | 99,706              |
| Diluted number of shares outstanding  | 99,435                          | 99,568              | 99,359                           | 100,246             |

STERIS plc  
**Consolidated Condensed Balance Sheets**  
(in thousands)

|   | March 31,<br>2024    | March 31,<br>2023    |
|---|----------------------|----------------------|
|   | (Unaudited)          |                      |
| <b>Assets</b>                             |                      |                      |
| <b>Current assets:</b>                    |                      |                      |
| Cash and cash equivalents                 | \$ 207,020           | \$ 208,357           |
| Accounts receivable, net                  | 1,008,315            | 864,988              |
| Inventories, net                          | 674,535              | 604,410              |
| Prepaid expenses and other current assets | 180,767              | 176,107              |
| Current assets held for sale              | 804,904              | 157,580              |
| <b>Total current assets</b>               | <b>2,875,541</b>     | <b>2,011,442</b>     |
| Property, plant, and equipment, net       | 1,765,180            | 1,632,775            |
| Lease right-of-use assets, net            | 173,201              | 166,553              |
| Goodwill                                  | 4,070,712            | 3,879,219            |
| Intangibles, net                          | 2,119,282            | 2,076,699            |
| Other assets                              | 67,923               | 77,892               |
| Non-current assets held for sale          | —                    | 977,259              |
| <b>Total assets</b>                       | <b>\$ 11,071,839</b> | <b>\$ 10,821,839</b> |
| <b>Liabilities and equity</b>             |                      |                      |
| <b>Current liabilities:</b>               |                      |                      |
| Accounts payable                          | \$ 251,723           | \$ 264,165           |
| Other current liabilities                 | 623,534              | 547,037              |
| Current liabilities held for sale         | 64,012               | 50,642               |
| <b>Total current liabilities</b>          | <b>939,269</b>       | <b>861,844</b>       |
| Long-term indebtedness                    | 3,120,162            | 3,018,655            |
| Other liabilities                         | 697,062              | 740,122              |
| Non-current liabilities held for sale     | —                    | 114,046              |
| <b>Total equity</b>                       | <b>6,315,346</b>     | <b>6,087,172</b>     |
| <b>Total liabilities and equity</b>       | <b>\$ 11,071,839</b> | <b>\$ 10,821,839</b> |

## STERIS plc

### Segment Data

(in thousands)

Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment's gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments.

|   | Three Months Ended<br>March 31, |                     | Twelve Months Ended<br>March 31, |                     |
|---|---------------------------------|---------------------|----------------------------------|---------------------|
|   | 2024                            | 2023                | 2024                             | 2023                |
|   | (unaudited)                     | (unaudited)         | (unaudited)                      | (unaudited)         |
| <b>Revenues:</b>  |                                 |                     |                                  |                     |
| Healthcare  | \$ 1,007,862                    | \$ 884,648          | \$ 3,613,019                     | \$ 3,085,131        |
| AST   | 250,897                         | 239,148             | 953,980                          | 914,431             |
| Life Sciences   | 160,628                         | 157,456             | 571,702                          | 536,704             |
| <b>Total revenues</b>   | <b>\$ 1,419,387</b>             | <b>\$ 1,281,252</b> | <b>\$ 5,138,701</b>              | <b>\$ 4,536,266</b> |
| <b>Operating income (loss):</b>   |                                 |                     |                                  |                     |
| Healthcare  | \$ 245,224                      | \$ 208,787          | \$ 871,358                       | \$ 706,020          |
| AST   | 114,215                         | 105,782             | 439,744                          | 429,020             |
| Life Sciences   | 64,486                          | 61,052              | 221,349                          | 210,225             |
| Corporate   | (88,044)                        | (68,607)            | (348,497)                        | (264,974)           |
| <b>Total operating income before adjustments</b>                              | <b>\$ 335,881</b>               | <b>\$ 307,014</b>   | <b>\$ 1,183,954</b>              | <b>\$ 1,080,291</b> |
| <b>Less: Adjustments</b>  |                                 |                     |                                  |                     |
| Amortization of acquired intangible assets                                    | \$ 67,760                       | \$ 64,996           | \$ 266,420                       | \$ 256,355          |
| Acquisition and integration related charges                                   | 1,217                           | 5,523               | 25,526                           | 23,486              |
| Tax restructuring (benefits) costs  | (32)                            | 129                 | 620                              | 661                 |
| Gain on fair value adjustment of acquisition related contingent consideration | —                               | —                   | —                                | (3,100)             |
| Net loss (gain) on divestiture of businesses                                  | 873                             | (4,006)             | 873                              | (67)                |
| Amortization of inventory and property "step up" to fair value                | 1,366                           | 6,336               | 10,032                           | 11,370              |
| Restructuring charges   | 44,363                          | 359                 | 44,365                           | 485                 |
| <b>Total operating income</b>   | <b>\$ 220,334</b>               | <b>\$ 233,677</b>   | <b>\$ 836,118</b>                | <b>\$ 791,101</b>   |

**STERIS plc**  
**Consolidated Condensed Statements of Cash Flows**  
(in thousands)

|   | <b>Twelve Months Ended March 31,</b> |                   |
|---|--------------------------------------|-------------------|
|   | <b>2024</b>                          | <b>2023</b>       |
|   | (Unaudited)                          | (Unaudited)       |
| <b>Operating activities:</b>  |                                      |                   |
| Net income  | \$ 380,079                           | \$ 105,813        |
| Non-cash items  | 735,832                              | 901,157           |
| Changes in operating assets and liabilities                           | (142,637)                            | (250,023)         |
| <b>Net cash provided by operating activities</b>                      | <b>973,274</b>                       | <b>756,947</b>    |
| <b>Investing activities:</b>  |                                      |                   |
| Purchases of property, plant, equipment, and intangibles, net         | (360,326)                            | (361,969)         |
| Proceeds from the sale of property, plant, equipment, and intangibles | 7,381                                | 14,587            |
| Proceeds from the sale of businesses                                  | 9,458                                | 6,624             |
| Proceeds from the sale of investments                                 | 3,882                                | —                 |
| Investment in convertible notes                                       | (1,500)                              | —                 |
| Acquisition of businesses, net of cash acquired                       | (546,256)                            | (42,572)          |
| <b>Net cash used in investing activities</b>                          | <b>(887,361)</b>                     | <b>(383,330)</b>  |
| <b>Financing activities:</b>  |                                      |                   |
| Payments on term loans  | (60,000)                             | (156,875)         |
| Payments on Private Placement Senior Notes                            | —                                    | (91,000)          |
| Proceeds under credit facilities, net                                 | 181,486                              | 241,657           |
| Acquisition related deferred or contingent consideration              | (6,242)                              | (1,471)           |
| Repurchases of ordinary shares  | (11,765)                             | (308,565)         |
| Cash dividends paid to ordinary shareholders                          | (200,570)                            | (183,498)         |
| Distributions to noncontrolling interest                              | (1,561)                              | (794)             |
| Contributions from noncontrolling interest                            | 2,994                                | —                 |
| Stock option and other equity transactions, net                       | 10,472                               | 1,828             |
| <b>Net cash used in financing activities</b>                          | <b>(85,186)</b>                      | <b>(498,718)</b>  |
| Effect of exchange rate changes on cash and cash equivalents          | (2,064)                              | (14,862)          |
| Decrease in cash and cash equivalents                                 | (1,337)                              | (139,963)         |
| Cash and cash equivalents at beginning of period                      | 208,357                              | 348,320           |
| Cash and cash equivalents at end of period                            | <b>\$ 207,020</b>                    | <b>\$ 208,357</b> |

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies.

|   | <b>Twelve Months Ended March 31,</b> |                   |
|---|--------------------------------------|-------------------|
|   | <b>2024</b>                          | <b>2023</b>       |
|   | (Unaudited)                          | (Unaudited)       |
| <b>Calculation of Free Cash Flow:</b>                                 |                                      |                   |
| Cash flows from operating activities                                  | \$ 973,274                           | \$ 756,947        |
| Purchases of property, plant, equipment, and intangibles, net         | (360,326)                            | (361,969)         |
| Proceeds from the sale of property, plant, equipment, and intangibles | 7,381                                | 14,587            |
| <b>Free Cash Flow</b>   | <b>\$ 620,329</b>                    | <b>\$ 409,565</b> |

**STERIS plc**  
**Non-GAAP Financial Measures**  
(in thousands, except per share data)

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our U.S. GAAP financial measures and the reconciliation to the corresponding U.S. GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.

**Three months ended March 31, (unaudited)**

|   | As reported, U.S. GAAP |                     | Impact of Acquisitions |             | Impact of Divestitures |      | Impact of Foreign Currency Movements | U.S. GAAP Growth | Organic Growth | Constant Currency Organic Growth |
|---|------------------------|---------------------|------------------------|-------------|------------------------|------|--------------------------------------|------------------|----------------|----------------------------------|
|   | 2024                   | 2023                | 2024                   | 2023        | 2024                   | 2023 | 2024                                 | 2024             | 2024           | 2024                             |
|   |                        |                     |                        |             |                        |      |                                      |                  |                |                                  |
| <b>Segment revenues:</b>                |                        |                     |                        |             |                        |      |                                      |                  |                |                                  |
| Healthcare                              | \$ 1,007,862           | \$ 884,648          | \$ 44,995              | \$ —        | \$ 2,750               |      | 13.9 %                               | 8.8 %            | 8.5 %          |                                  |
| AST                                     | 250,897                | 239,148             | —                      | —           | 646                    |      | 4.9 %                                | 4.9 %            | 4.6 %          |                                  |
| Life Sciences                           | 160,628                | 157,456             | —                      | —           | 666                    |      | 2.0 %                                | 2.0 %            | 1.6 %          |                                  |
| <b>Total - Continuing Operations</b>    | <b>\$ 1,419,387</b>    | <b>\$ 1,281,252</b> | <b>\$ 44,995</b>       | <b>\$ —</b> | <b>\$ 4,062</b>        |      | <b>10.8 %</b>                        | <b>7.3 %</b>     | <b>7.0 %</b>   |                                  |
| <b>Dental - Discontinued Operations</b> | <b>103,794</b>         | <b>103,585</b>      | <b>—</b>               | <b>—</b>    | <b>(29)</b>            |      | <b>0.2 %</b>                         | <b>0.2 %</b>     | <b>0.2 %</b>   |                                  |
| <b>Total Company</b>                    | <b>\$ 1,523,181</b>    | <b>\$ 1,384,837</b> | <b>\$ 44,995</b>       | <b>\$ —</b> | <b>\$ 4,033</b>        |      | <b>10.0 %</b>                        | <b>6.7 %</b>     | <b>6.4 %</b>   |                                  |

**Twelve months ended March 31, (unaudited)**

|   | As reported, U.S. GAAP |                     | Impact of Acquisitions |             | Impact of Divestitures |      | Impact of Foreign Currency Movements | U.S. GAAP Growth | Organic Growth | Constant Currency Organic Growth |
|---|------------------------|---------------------|------------------------|-------------|------------------------|------|--------------------------------------|------------------|----------------|----------------------------------|
|   | 2024                   | 2023                | 2024                   | 2023        | 2024                   | 2023 | 2024                                 | 2024             | 2024           | 2024                             |
|   |                        |                     |                        |             |                        |      |                                      |                  |                |                                  |
| <b>Segment revenues:</b>                |                        |                     |                        |             |                        |      |                                      |                  |                |                                  |
| Healthcare                              | \$ 3,613,019           | \$ 3,085,131        | \$ 119,285             | \$ —        | \$ 13,584              |      | 17.1 %                               | 13.2 %           | 12.8 %         |                                  |
| AST                                     | 953,980                | 914,431             | —                      | —           | 10,449                 |      | 4.3 %                                | 4.3 %            | 3.2 %          |                                  |
| Life Sciences                           | 571,702                | 536,704             | —                      | —           | 3,621                  |      | 6.5 %                                | 6.5 %            | 5.8 %          |                                  |
| <b>Total - Continuing Operations</b>    | <b>\$ 5,138,701</b>    | <b>\$ 4,536,266</b> | <b>\$ 119,285</b>      | <b>\$ —</b> | <b>\$ 27,654</b>       |      | <b>13.3 %</b>                        | <b>10.7 %</b>    | <b>10.0 %</b>  |                                  |
| <b>Dental - Discontinued Operations</b> | <b>407,027</b>         | <b>421,573</b>      | <b>—</b>               | <b>—</b>    | <b>1,697</b>           |      | <b>(3.5)%</b>                        | <b>(3.5)%</b>    | <b>(3.9)%</b>  |                                  |
| <b>Total Company</b>                    | <b>\$ 5,545,728</b>    | <b>\$ 4,957,839</b> | <b>\$ 119,285</b>      | <b>\$ —</b> | <b>\$ 29,351</b>       |      | <b>11.9 %</b>                        | <b>9.5 %</b>     | <b>8.9 %</b>   |                                  |

STERIS plc  
Non-GAAP Financial Measures (Continued)  
(in thousands, except per share data)

Three months ended March 31, (unaudited)

|  | Continuing Operations |            |                        |            |  |            |   |           |  |            |  |         |  |         |                            |         |
|--|-----------------------|------------|------------------------|------------|--|------------|---|-----------|--|------------|--|---------|--|---------|----------------------------|---------|
|  | Gross Profit          |            | Income from Operations |            | Income from continuing operations, net of income tax |            | (Loss) income from discontinued operations, net of income tax |           | Net (loss) income attributable to shareholders |            | Diluted EPS from continuing operations |         | Diluted EPS from discontinued operations |         | Diluted EPS <sup>(2)</sup> |         |
|  | 2024                  | 2023       | 2024                   | 2023       | 2024   | 2023       | 2024  | 2023      | 2024   | 2023       | 2024                                   | 2023    | 2024                                     | 2023    | 2024                       | 2023    |
| <b>As reported, U.S. GAAP</b>                                  | <b>\$ 582,902</b>     | \$ 546,402 | <b>\$ 220,334</b>      | \$ 233,677 | <b>\$ 153,299</b>                                    | \$ 182,199 | <b>\$(154,301)</b>  | \$ 4,765  | <b>\$ (1,377)</b>                              | \$ 187,225 | <b>\$ 1.54</b>                         | \$ 1.83 | <b>\$ (1.55)</b>                         | \$ 0.05 | <b>\$ (0.01)</b>           | \$ 1.88 |
| Adjustments:   |                       |            |                        |            |  |            |   |           |  |            |  |         |  |         |                            |         |
| Amortization of acquired intangible assets                     | 393                   | 620        | 67,760                 | 64,996     |  |            |   |           |  |            |  |         |  |         |                            |         |
| Acquisition and integration related charges                    | 1,884                 | 3,027      | 1,217                  | 5,523      |  |            |   |           |  |            |  |         |  |         |                            |         |
| Redomiciliation and tax restructuring costs                    | —                     | —          | (32)                   | 129        |  |            |   |           |  |            |  |         |  |         |                            |         |
| Net loss (gain) on divestiture of businesses                   | 176                   | 244        | 873                    | (4,006)    |  |            |   |           |  |            |  |         |  |         |                            |         |
| Amortization of inventory and property "step up" to fair value | 635                   | 5,429      | 1,366                  | 6,336      |  |            |   |           |  |            |  |         |  |         |                            |         |
| Restructuring charges  | 18,321                | —          | 44,363                 | 359        |  |            |   |           |  |            |  |         |  |         |                            |         |
| Net impact of adjustments after tax <sup>(1)</sup>             |                       |            |                        |            | 87,199   | 31,293     | 170,488   | 10,722    | 257,687  | 42,015     |  |         |  |         |                            |         |
| Net EPS impact   |                       |            |                        |            |  |            |   |           |  |            | 0.87                                   | 0.32    | 1.71                                     | 0.11    | 2.59                       | 0.42    |
| <b>Adjusted</b>  | <b>\$ 604,311</b>     | \$ 555,722 | <b>\$ 335,881</b>      | \$ 307,014 | <b>\$ 240,498</b>                                    | \$ 213,492 | <b>\$ 16,187</b>  | \$ 15,487 | <b>\$ 256,310</b>                              | \$ 229,240 | <b>\$ 2.41</b>                         | \$ 2.15 | <b>\$ 0.16</b>                           | \$ 0.16 | <b>\$ 2.58</b>             | \$ 2.30 |

<sup>(1)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments.

<sup>(2)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Non-GAAP Financial Measures (Continued)  
(in thousands, except per share data)

Twelve months ended March 31, (unaudited)

|   | Continuing Operations |                    |                        |                    |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
|---|-----------------------|--------------------|------------------------|--------------------|--|-------------------|---|--------------------|---|-------------------|--|----------------|--|------------------|----------------------------|----------------|
|   | Gross Profit          |                    | Income from Operations |                    | Income from continuing operations, net of income tax |                   | (Loss) income from discontinued operations, net of income tax |                    | Net income attributable to shareholders |                   | Diluted EPS from continuing operations |                | Diluted EPS from discontinued operations |                  | Diluted EPS <sup>(2)</sup> |                |
|   | 2024                  | 2023               | 2024                   | 2023               | 2024   | 2023              | 2024  | 2023               | 2024                                    | 2023              | 2024                                   | 2023           | 2024                                     | 2023             | 2024                       | 2023           |
| <b>As reported, U.S. GAAP</b>   | <b>\$2,218,160</b>    | <b>\$1,980,726</b> | <b>\$ 836,118</b>      | <b>\$ 791,101</b>  | <b>\$ 553,280</b>                                    | <b>\$ 556,197</b> | <b>\$(173,201)</b>  | <b>\$(450,384)</b> | <b>\$378,239</b>                        | <b>\$ 107,030</b> | <b>\$ 5.55</b>                         | <b>\$ 5.56</b> | <b>\$ (1.74)</b>                         | <b>\$ (4.49)</b> | <b>\$ 3.81</b>             | <b>\$ 1.07</b> |
| Adjustments:  |                       |                    |                        |                    |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Amortization of acquired intangible assets                                    | 2,049                 | 1,891              | 266,420                | 256,355            |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Acquisition and integration related charges                                   | 3,264                 | 5,657              | 25,526                 | 23,486             |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Redomiciliation and tax restructuring costs                                   | —                     | —                  | 620                    | 661                |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Gain on fair value adjustment of acquisition related contingent consideration | —                     | —                  | —                      | (3,100)            |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Net loss (gain) on divestiture of businesses                                  | 176                   | 3,126              | 873                    | (67)               |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Amortization of inventory and property "step up" to fair value                | 7,060                 | 9,846              | 10,032                 | 11,370             |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Restructuring charges   | 18,320                | —                  | 44,365                 | 485                |  |                   |   |                    |   |                   |  |                |  |                  |                            |                |
| Net impact of adjustments after tax <sup>(1)</sup>                            |                       |                    |                        |                    | 263,429  | 198,894           | 235,960   | 516,293            | 499,389                                 | 715,187           |  |                |  |                  |                            |                |
| Net EPS impact  |                       |                    |                        |                    |  |                   |   |                    |   |                   | 2.65                                   | 1.98           | 2.37                                     | 5.15             | 5.02                       | 7.13           |
| <b>Adjusted</b>   | <b>\$2,249,029</b>    | <b>\$2,001,246</b> | <b>\$1,183,954</b>     | <b>\$1,080,291</b> | <b>\$ 816,709</b>                                    | <b>\$ 755,091</b> | <b>\$ 62,759</b>  | <b>\$ 65,909</b>   | <b>\$877,628</b>                        | <b>\$ 822,217</b> | <b>\$ 8.20</b>                         | <b>\$ 7.54</b> | <b>\$ 0.63</b>                           | <b>\$ 0.66</b>   | <b>\$ 8.83</b>             | <b>\$ 8.20</b> |

<sup>(1)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments.

<sup>(2)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Non-GAAP Financial Measures (Continued)  
(in thousands, except per share data)

**FY 2025 Outlook**

**Twelve Months  
Ended March 31, 2025  
(Outlook)\*\***

|  |                        |
|--|------------------------|
| Net income from continuing operations per diluted share          | \$6.55 - \$6.75        |
| Amortization of acquired intangible assets                       | 2.06                   |
| Acquisition and integration related charges                      | 0.02                   |
| Restructuring  | 0.42                   |
| Adjusted net income from continuing operations per diluted share | <u>\$9.05 - \$9.25</u> |
| Cash flows from operating activities                             | \$1,060,000            |
| Purchases of property, plant, equipment, and intangibles, net    | <u>(360,000)</u>       |
| Free Cash Flow   | <u>\$700,000</u>       |

\*\*\* All amounts are estimates.



STERIS plc  
Unaudited Supplemental Financial Data  
Fourth Quarter Fiscal 2024  
For the Periods Ending March 31, 2024 and 2023

|   | FY 2024             | FY 2023             | FY 2024             | FY 2023             |
|---|---------------------|---------------------|---------------------|---------------------|
|   | Q4                  | Q4                  | YTD                 | YTD                 |
| <b>Total Company Revenues - Continuing Operations</b> |                     |                     |                     |                     |
| Consumables   | \$ 403,637          | \$ 361,481          | \$ 1,502,378        | \$ 1,293,284        |
| Service   | 633,150             | 582,021             | 2,374,747           | 2,172,512           |
| Total Recurring                                       | \$ 1,036,787        | \$ 943,502          | \$ 3,877,125        | \$ 3,465,796        |
| Capital Equipment                                     | \$ 382,600          | \$ 337,750          | \$ 1,261,576        | \$ 1,070,470        |
| <b>Total Revenues</b>                                 | <b>\$ 1,419,387</b> | <b>\$ 1,281,252</b> | <b>\$ 5,138,701</b> | <b>\$ 4,536,266</b> |
| <b>Ireland Revenues</b>                               | <b>\$ 22,659</b>    | <b>\$ 21,280</b>    | <b>\$ 82,695</b>    | <b>\$ 74,292</b>    |
| Ireland Revenues as a % of Total                      | 2 %                 | 2 %                 | 2 %                 | 2 %                 |
| <b>United States Revenues</b>                         | <b>\$ 1,036,039</b> | <b>\$ 917,790</b>   | <b>\$ 3,751,437</b> | <b>\$ 3,254,373</b> |
| United States Revenues as a % of Total                | 73 %                | 71 %                | 73 %                | 71 %                |
| <b>International Revenues</b>                         | <b>\$ 360,689</b>   | <b>\$ 342,182</b>   | <b>\$ 1,304,569</b> | <b>\$ 1,207,601</b> |
| International Revenues as a % of Total                | 25 %                | 27 %                | 25 %                | 27 %                |

| <b>Segment Data - Continuing Operations</b> | FY 2024            | FY 2023            | FY 2024             | FY 2023             |
|---|--------------------|--------------------|---------------------|---------------------|
|   | Q4                 | Q4                 | YTD                 | YTD                 |
| <b>Healthcare Revenues</b>                  |                    |                    |                     |                     |
| Consumables                                 | \$ 332,683         | \$ 292,424         | \$ 1,248,424        | \$ 1,050,316        |
| Service                                     | 343,484            | 314,478            | 1,273,058           | 1,138,225           |
| Total Recurring                             | \$ 676,167         | \$ 606,902         | \$ 2,521,482        | \$ 2,188,541        |
| Capital Equipment                           | 331,695            | 277,746            | 1,091,537           | 896,590             |
| Total Healthcare Revenues                   | \$ 1,007,862       | \$ 884,648         | \$ 3,613,019        | \$ 3,085,131        |
| <b>Segment Operating Income</b>             | <b>\$ 245,224</b>  | <b>\$ 208,787</b>  | <b>\$ 871,358</b>   | <b>\$ 706,020</b>   |
| <b>AST Revenues</b>                         |                    |                    |                     |                     |
| Service                                     | \$ 244,247         | \$ 227,469         | \$ 939,461          | \$ 887,971          |
| Capital Equipment                           | 6,650              | 11,679             | 14,519              | 26,460              |
| Total AST Revenues                          | \$ 250,897         | \$ 239,148         | \$ 953,980          | \$ 914,431          |
| <b>Segment Operating Income</b>             | <b>\$ 114,215</b>  | <b>\$ 105,782</b>  | <b>\$ 439,744</b>   | <b>\$ 429,020</b>   |
| <b>Life Sciences Revenues</b>               |                    |                    |                     |                     |
| Consumables                                 | \$ 70,401          | \$ 68,527          | \$ 251,580          | \$ 241,114          |
| Service                                     | 45,972             | 40,604             | 164,602             | 148,170             |
| Total Recurring                             | \$ 116,373         | \$ 109,131         | \$ 416,182          | \$ 389,284          |
| Capital Equipment                           | 44,255             | 48,325             | 155,520             | 147,420             |
| Total Life Sciences Revenues                | \$ 160,628         | \$ 157,456         | \$ 571,702          | \$ 536,704          |
| <b>Segment Operating Income</b>             | <b>\$ 64,486</b>   | <b>\$ 61,052</b>   | <b>\$ 221,349</b>   | <b>\$ 210,225</b>   |
| <b>Corporate Operating Loss</b>             | <b>\$ (88,044)</b> | <b>\$ (68,607)</b> | <b>\$ (348,497)</b> | <b>\$ (264,974)</b> |

| <b>Discontinued Operations</b> | FY 2024           | FY 2023           | FY 2024           | FY 2023           |
|--------------------------------|-------------------|-------------------|-------------------|-------------------|
|                                | Q4                | Q4                | YTD               | YTD               |
| <b>Dental revenues</b>         | <b>\$ 103,794</b> | <b>\$ 103,585</b> | <b>\$ 407,027</b> | <b>\$ 421,573</b> |
| <b>Dental operating income</b> | <b>22,448</b>     | <b>21,535</b>     | <b>86,500</b>     | <b>89,527</b>     |

| <b>Other Data</b>   | FY 2024           | FY 2023           | FY 2024       | FY 2023       |
|---|-------------------|-------------------|---------------|---------------|
|   | Q4                | Q4                | YTD           | YTD           |
| Healthcare Backlog  | \$ 353,833        | \$ 494,650        |               |               |
| Life Sciences Backlog   | 71,400            | 104,900           |               |               |
| <b>Total Backlog - Continuing Operations</b>                            | <b>\$ 425,233</b> | <b>\$ 599,550</b> |               |               |
| <b>As reported, U.S. GAAP Income Tax Rate - Continuing Operations</b>   | <b>19.6 %</b>     | <b>10.4 %</b>     | <b>21.3 %</b> | <b>18.2 %</b> |
| <b>Adjusted Income Tax Rate - Continuing Operations</b>                 | <b>21.4 %</b>     | <b>23.0 %</b>     | <b>22.3 %</b> | <b>22.4 %</b> |
| <b>As reported, U.S. GAAP Income Tax Rate - Discontinued Operations</b> | <b>24.3 %</b>     | <b>157.6 %</b>    | <b>24.3 %</b> | <b>13.9 %</b> |
| <b>Adjusted Income Tax Rate - Discontinued Operations</b>               | <b>27.9 %</b>     | <b>30.3 %</b>     | <b>27.5 %</b> | <b>26.5 %</b> |

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.

## STERIS plc

## Unaudited Supplemental Financial Data

As a result of the agreement to divest our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability, as required.

## Quarterly as reported, U.S. GAAP Results

| Quarters Ended  | Full Year    | March 31,    | December 31, | September 30, | June 30,     |
|---|--------------|--------------|--------------|---------------|--------------|
| <b>Fiscal 2024</b>  |              |              |              |               |              |
| Revenues  | \$ 5,138,701 | \$ 1,419,387 | \$ 1,297,724 | \$ 1,238,204  | \$ 1,183,386 |
| Cost of revenues  | 2,920,541    | 836,485      | 737,698      | 691,976       | 654,382      |
| Gross profit  | 2,218,160    | 582,902      | 560,026      | 546,228       | 529,004      |
| Percentage of revenues  | 43.2 %       | 41.1 %       | 43.2 %       | 44.1 %        | 44.7 %       |
| Income from continuing operations before income tax expense             | 702,810      | 190,575      | 189,602      | 155,852       | 166,781      |
| Income tax expense  | 149,530      | 37,276       | 40,999       | 35,055        | 36,200       |
| Income from continuing operations, net of income tax                    | 553,280      | 153,299      | 148,603      | 120,797       | 130,581      |
| Loss from discontinued operations, net of income tax                    | (173,201)    | (154,301)    | (7,658)      | (4,451)       | (6,791)      |
| Net income (loss)   | 380,079      | (1,002)      | 140,945      | 116,346       | 123,790      |
| Net income (loss) attributable to shareholders                          | \$ 378,239   | \$ (1,377)   | \$ 140,743   | \$ 115,319    | \$ 123,554   |
| <b>Diluted earnings per ordinary share attributable to shareholders</b> |              |              |              |               |              |
| Continuing operations   | \$ 5.55      | \$ 1.54      | \$ 1.49      | \$ 1.20       | \$ 1.31      |
| Discontinued operations   | \$ (1.74)    | \$ (1.55)    | \$ (0.08)    | \$ (0.04)     | \$ (0.07)    |
| Total   | \$ 3.81      | \$ (0.01)    | \$ 1.42      | \$ 1.16       | \$ 1.25      |
| <b>Fiscal 2023</b>  |              |              |              |               |              |
| Revenues  | \$ 4,536,266 | \$ 1,281,252 | \$ 1,112,431 | \$ 1,090,939  | \$ 1,051,644 |
| Cost of revenues  | 2,555,540    | 734,850      | 634,244      | 608,627       | 577,819      |
| Gross profit  | 1,980,726    | 546,402      | 478,187      | 482,312       | 473,825      |
| Percentage of revenues  | 43.7 %       | 42.6 %       | 43.0 %       | 44.2 %        | 45.1 %       |
| Income from continuing operations before income tax expense             | 680,266      | 203,402      | 171,539      | 159,325       | 146,000      |
| Income tax expense  | 124,069      | 21,203       | 40,534       | 35,417        | 26,915       |
| Income from continuing operations, net of income tax                    | 556,197      | 182,199      | 131,005      | 123,908       | 119,085      |
| Income (loss) from discontinued operations, net of income tax           | (450,384)    | 4,765        | (7,680)      | (439,139)     | (8,330)      |
| Net income (loss)   | 105,813      | 186,964      | 123,325      | (315,231)     | 110,755      |
| Net income (loss) attributable to shareholders                          | \$ 107,030   | \$ 187,225   | \$ 123,828   | \$ (315,285)  | \$ 111,262   |
| <b>Diluted earnings per ordinary share attributable to shareholders</b> |              |              |              |               |              |
| Continuing operations   | \$ 5.56      | \$ 1.83      | \$ 1.31      | \$ 1.24       | \$ 1.19      |
| Discontinued operations   | \$ (4.49)    | \$ 0.05      | \$ (0.08)    | \$ (4.39)     | \$ (0.08)    |
| Total   | \$ 1.07      | \$ 1.88      | \$ 1.24      | \$ (3.15)     | \$ 1.10      |

Other than the changes to retrospectively adjust the presentation of our discontinued operations as discussed above, this supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures.

## STERIS plc

## Unaudited Supplemental Financial Data

As a result of the agreement to divest our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability, as required.

## Adjusted Quarterly Results (Non-GAAP)

| Quarters Ended  | Full Year    | March 31,    | December 31, | September 30, | June 30,     |
|---|--------------|--------------|--------------|---------------|--------------|
| <b>Fiscal 2024</b>  |              |              |              |               |              |
| Revenues  | \$ 5,138,701 | \$ 1,419,387 | \$ 1,297,724 | \$ 1,238,204  | \$ 1,183,386 |
| Cost of revenues  | 2,889,672    | 815,076      | 730,724      | 690,624       | 653,248      |
| Gross profit  | 2,249,029    | 604,311      | 567,000      | 547,580       | 530,138      |
| Percentage of revenues  | 43.8 %       | 42.6 %       | 43.7 %       | 44.2 %        | 44.8 %       |
| Income from continuing operations before income tax expense             | 1,050,646    | 306,122      | 267,365      | 242,400       | 234,759      |
| Income tax expense  | 233,937      | 65,624       | 59,578       | 56,478        | 52,257       |
| Income from continuing operations, net of income tax                    | 816,709      | 240,498      | 207,787      | 185,922       | 182,502      |
| Income from discontinued operations, net of income tax                  | 62,759       | 16,187       | 13,344       | 17,281        | 15,947       |
| Net income  | 879,468      | 256,685      | 221,131      | 203,203       | 198,449      |
| Net income attributable to shareholders                                 | \$ 877,628   | \$ 256,310   | \$ 220,929   | \$ 202,176    | \$ 198,213   |
| <b>Diluted earnings per ordinary share attributable to shareholders</b> |              |              |              |               |              |
| Continuing operations   | \$ 8.20      | \$ 2.41      | \$ 2.09      | \$ 1.86       | \$ 1.84      |
| Discontinued operations   | \$ 0.63      | \$ 0.16      | \$ 0.13      | \$ 0.17       | \$ 0.16      |
| Total   | \$ 8.83      | \$ 2.58      | \$ 2.22      | \$ 2.03       | \$ 2.00      |
| <b>Fiscal 2023</b>  |              |              |              |               |              |
| Revenues  | \$ 4,536,266 | \$ 1,281,252 | \$ 1,112,431 | \$ 1,090,939  | \$ 1,051,644 |
| Cost of revenues  | 2,535,020    | 725,530      | 631,752      | 603,675       | 574,063      |
| Gross profit  | 2,001,246    | 555,722      | 480,679      | 487,264       | 477,581      |
| Percentage of revenues  | 44.1 %       | 43.4 %       | 43.2 %       | 44.7 %        | 45.4 %       |
| Income from continuing operations before income tax expense             | 973,537      | 277,355      | 244,057      | 230,247       | 221,878      |
| Income tax expense  | 218,446      | 63,863       | 56,793       | 52,010        | 45,780       |
| Income from continuing operations, net of income tax                    | 755,091      | 213,492      | 187,264      | 178,237       | 176,098      |
| Income from discontinued operations, net of income tax                  | 65,909       | 15,487       | 14,522       | 21,399        | 14,501       |
| Net income  | 821,000      | 228,979      | 201,786      | 199,636       | 190,599      |
| Net income attributable to shareholders                                 | \$ 822,217   | \$ 229,240   | \$ 202,289   | \$ 199,582    | \$ 191,106   |
| <b>Diluted earnings per ordinary share attributable to shareholders</b> |              |              |              |               |              |
| Continuing operations   | \$ 7.54      | \$ 2.15      | \$ 1.87      | \$ 1.78       | \$ 1.75      |
| Discontinued operations   | \$ 0.66      | \$ 0.16      | \$ 0.14      | \$ 0.21       | \$ 0.14      |
| Total   | \$ 8.20      | \$ 2.30      | \$ 2.02      | \$ 1.99       | \$ 1.90      |

Other than the changes to retrospectively adjust the presentation of our discontinued operations as discussed above, this supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures.

STERIS plc  
Unaudited Supplementary Financial Data

Quarters Ended June 30, U.S.GAAP to Adjusted (Non-GAAP) Reconciliation

|   | Three months ended June 30, (unaudited) |            |                        |            |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
|---|---|------------|------------------------|------------|--|------------|-------------------|------------|---|---|----------------|--|------------------|--|----------------|----------------------------|--|
|   | Continuing Operations                   |            |                        |            |  |            |                   |            | (Loss) income from discontinued operations, net of income tax | Net income attributable to shareholders |                | Diluted EPS from continuing operations |                  | Diluted EPS from discontinued operations |                | Diluted EPS <sup>(2)</sup> |  |
|   | Gross Profit                            |            | Income from Operations |            | Income from continuing operations, net of income tax |            |                   |            |   |   |                |  |                  |  |                |                            |  |
|   | 2023                                    | 2022       | 2023                   | 2022       | 2023   | 2022       | 2023              | 2022       | 2023  | 2022                                    | 2023           | 2022                                   | 2023             | 2022                                     | 2023           | 2022                       |  |
| <b>As reported, U.S. GAAP</b>   | <b>\$ 529,004</b>                       | \$ 473,825 | <b>\$ 197,761</b>      | \$ 169,455 | <b>\$ 130,581</b>                                    | \$ 119,085 | <b>\$ (6,791)</b> | \$ (8,330) | <b>\$ 123,554</b>   | \$ 111,262                              | <b>\$ 1.31</b> | \$ 1.19                                | <b>\$ (0.07)</b> | \$ (0.08)                                | <b>\$ 1.25</b> | \$ 1.10                    |  |
| Adjustments:  |   |            |                        |            |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Amortization of acquired intangible assets                                    | 575                                     | 418        | 64,092                 | 63,840     |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Acquisition and integration related (credits) charges                         | (38)                                    | 589        | 2,237                  | 9,659      |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Redomiciliation and tax restructuring costs                                   | —                                       | —          | 9                      | 173        |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Gain on fair value adjustment of acquisition related contingent consideration | —                                       | —          | —                      | (3,100)    |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Net loss on divestiture of businesses   | —                                       | 534        | —                      | 3,878      |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Amortization of inventory and property "step up" to fair value                | 597                                     | 2,215      | 1,622                  | 1,416      |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Restructuring charges   | —                                       | —          | 19                     | 26         |  |            |                   |            |   |   |                |  |                  |  |                |                            |  |
| Net impact of adjustments after tax <sup>(1)</sup>                            |   |            |                        |            | 51,921   | 57,013     | 22,738            | 22,831     | 74,659  | 79,844                                  |                |  |                  |  |                |                            |  |
| Net EPS impact  |   |            |                        |            |  |            |                   |            |   |   | 0.53           | 0.56                                   | 0.23             | 0.22                                     | 0.75           | 0.80                       |  |
| <b>Adjusted</b>   | <b>\$ 530,138</b>                       | \$ 477,581 | <b>\$ 265,740</b>      | \$ 245,347 | <b>\$ 182,502</b>                                    | \$ 176,098 | <b>\$ 15,947</b>  | \$ 14,501  | <b>\$ 198,213</b>   | \$ 191,106                              | <b>\$ 1.84</b> | \$ 1.75                                | <b>\$ 0.16</b>   | \$ 0.14                                  | <b>\$ 2.00</b> | \$ 1.90                    |  |

<sup>(1)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments.

<sup>(2)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Unaudited Supplementary Financial Data

Quarters Ended September 30, U.S.GAAP to Adjusted (Non- GAAP) Reconciliation

|  | Three months ended September 30, (unaudited) |            |                        |            |  |            |   |             |  |             |  |         |  |          |                            |          |
|--|--|------------|------------------------|------------|--|------------|---|-------------|--|-------------|--|---------|--|----------|----------------------------|----------|
|  | Continuing Operations                        |            |                        |            | Income from continuing operations, net of income tax |            | (Loss) income from discontinued operations, net of income tax |             | Net income (loss) attributable to shareholders |             | Diluted EPS from continuing operations |         | Diluted EPS from discontinued operations |          | Diluted EPS <sup>(2)</sup> |          |
|  | Gross Profit                                 |            | Income from Operations |            |  |            |   |             |  |             |  |         |  |          |                            |          |
|  | 2023   | 2022       | 2023                   | 2022       | 2023   | 2022       | 2023  | 2022        | 2023   | 2022        | 2023                                   | 2022    | 2023                                     | 2022     | 2023                       | 2022     |
| <b>As reported, U.S. GAAP</b>                                  | <b>\$ 546,228</b>                            | \$ 482,312 | <b>\$ 191,553</b>      | \$ 185,966 | <b>\$ 120,797</b>                                    | \$ 123,908 | <b>\$ (4,451)</b>   | \$(439,139) | <b>\$ 115,319</b>                              | \$(315,285) | <b>\$ 1.20</b>                         | \$ 1.24 | <b>\$ (0.04)</b>                         | \$(4.39) | <b>\$ 1.16</b>             | \$(3.15) |
| Adjustments:   |  |            |                        |            |  |            |   |             |  |             |  |         |  |          |                            |          |
| Amortization of acquired intangible assets                     | 574  | 431        | 69,846                 | 63,950     |  |            |   |             |  |             |  |         |  |          |                            |          |
| Acquisition and integration related charges                    | 225  | 1,182      | 15,808                 | 3,703      |  |            |   |             |  |             |  |         |  |          |                            |          |
| Redomiciliation and tax restructuring costs                    | —  | —          | —                      | 77         |  |            |   |             |  |             |  |         |  |          |                            |          |
| Net loss on divestiture of businesses                          | —  | 1,749      | —                      | 899        |  |            |   |             |  |             |  |         |  |          |                            |          |
| Amortization of inventory and property "step up" to fair value | 553  | 1,590      | 917                    | 2,231      |  |            |   |             |  |             |  |         |  |          |                            |          |
| Restructuring (credits) charges                                | —  | —          | (23)                   | 62         |  |            |   |             |  |             |  |         |  |          |                            |          |
| Net impact of adjustments after tax <sup>(1)</sup>             |  |            |                        |            | 65,125   | 54,329     | 21,732  | 460,538     | 86,857   | 514,867     |  |         |  |          |                            |          |
| Net EPS impact   |  |            |                        |            |  |            |   |             |  |             | 0.66                                   | 0.54    | 0.21                                     | 4.60     | 0.87                       | 5.14     |
| <b>Adjusted</b>  | <b>\$ 547,580</b>                            | \$ 487,264 | <b>\$ 278,101</b>      | \$ 256,888 | <b>\$ 185,922</b>                                    | \$ 178,237 | <b>\$ 17,281</b>  | \$ 21,399   | <b>\$ 202,176</b>                              | \$ 199,582  | <b>\$ 1.86</b>                         | \$ 1.78 | <b>\$ 0.17</b>                           | \$ 0.21  | <b>\$ 2.03</b>             | \$ 1.99  |

<sup>(1)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments.

<sup>(2)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.

STERIS plc  
Unaudited Supplementary Financial Data

Quarters Ended December 31, U.S.GAAP to Adjusted (Non-GAAP) Reconciliation

|  | Three months ended December 31, (unaudited) |            |                        |            |  |            |   |            |   |            |  |         |  |           |                            |         |
|--|---|------------|------------------------|------------|--|------------|---|------------|---|------------|--|---------|--|-----------|----------------------------|---------|
|  | Continuing Operations                       |            |                        |            | Income from continuing operations, net of income tax |            | (Loss) income from discontinued operations, net of income tax |            | Net income attributable to shareholders |            | Diluted EPS from continuing operations |         | Diluted EPS from discontinued operations |           | Diluted EPS <sup>(2)</sup> |         |
|  | Gross Profit                                |            | Income from Operations |            |  |            |   |            |   |            |  |         |  |           |                            |         |
|  | 2023  | 2022       | 2023                   | 2022       | 2023   | 2022       | 2023  | 2022       | 2023                                    | 2022       | 2023                                   | 2022    | 2023                                     | 2022      | 2023                       | 2022    |
| <b>As reported, U.S. GAAP</b>                                  | <b>\$ 560,026</b>                           | \$ 478,187 | <b>\$ 226,470</b>      | \$ 201,989 | <b>\$ 148,603</b>                                    | \$ 131,005 | <b>\$ (7,658)</b>   | \$ (7,680) | <b>\$ 140,743</b>                       | \$ 123,828 | <b>\$ 1.49</b>                         | \$ 1.31 | <b>\$ (0.08)</b>                         | \$ (0.08) | <b>\$ 1.42</b>             | \$ 1.24 |
| Adjustments:   |   |            |                        |            |  |            |   |            |   |            |  |         |  |           |                            |         |
| Amortization of acquired intangible assets                     | 507   | 422        | 64,724                 | 63,975     |  |            |   |            |   |            |  |         |  |           |                            |         |
| Acquisition and integration related charges                    | 1,192                                       | 859        | 6,263                  | 4,209      |  |            |   |            |   |            |  |         |  |           |                            |         |
| Redomiciliation and tax restructuring costs                    | —   | —          | 643                    | 282        |  |            |   |            |   |            |  |         |  |           |                            |         |
| Net loss (gain) on divestiture of businesses                   | —   | 599        | —                      | (838)      |  |            |   |            |   |            |  |         |  |           |                            |         |
| Amortization of inventory and property "step up" to fair value | 5,275                                       | 612        | 6,127                  | 1,387      |  |            |   |            |   |            |  |         |  |           |                            |         |
| Restructuring charges  | —   | —          | 6                      | 38         |  |            |   |            |   |            |  |         |  |           |                            |         |
| Net impact of adjustments after tax <sup>(1)</sup>             |   |            |                        |            | 59,184   | 56,259     | 21,002  | 22,202     | 80,186                                  | 78,461     |  |         |  |           |                            |         |
| Net EPS impact   |   |            |                        |            |  |            |   |            |   |            | 0.6                                    | 0.56    | 0.21                                     | 0.22      | 0.80                       | 0.78    |
| <b>Adjusted</b>  | <b>\$ 567,000</b>                           | \$ 480,679 | <b>\$ 304,233</b>      | \$ 271,042 | <b>\$ 207,787</b>                                    | \$ 187,264 | <b>\$ 13,344</b>  | \$ 14,522  | <b>\$ 220,929</b>                       | \$ 202,289 | <b>\$ 2.09</b>                         | \$ 1.87 | <b>\$ 0.13</b>                           | \$ 0.14   | <b>\$ 2.22</b>             | \$ 2.02 |

<sup>(1)</sup> The tax expense includes both the current and deferred income tax impact of the adjustments.

<sup>(2)</sup> Diluted EPS is calculated independently for Diluted EPS from continuing operations and Diluted EPS from discontinued operations. The sum of Diluted EPS from continuing operations and Diluted EPS from discontinued operations may not equal Diluted EPS due to rounding.